OREMAVEN
XMM 7,722.00 -2.63% YTD +5.6% OM ASX 450.55 -2.56% YTD +0.1% OM PRECIOUS 349.20 -2.24% YTD +2.5% OM EX-PREC 418.91 -2.72% YTD -1.1% XAU 4,115.59 +2.31% YTD -4.9% GLD 375.49 +0.81% YTD -5.2% GDX 85.75 +1.37% YTD -0.0% SIL 77.33 -1.00% YTD -7.3% COPX 70.23 -5.81% YTD -1.8% URNM 40.07 -2.79% YTD -27.0%
2026-11-06

← SYR management

Full background report

Shaun Verner

Managing Director / Chief Executive Officer

Career chronology

  • Current role; start date not established in reviewed sources: Syrah Resources Limited — Managing Director / Chief Executive Officer. Our Team (Syrah Our Team, Board of Directors, lines 57–59)

  • 2016-10 to current; CEO/MD from 2017-02: Syrah Resources Limited — Joined October 2016; appointed Managing Director and CEO February 2017. Syrah Resources investor presentation / management biographies (Company leadership biographies; current role cross-checked in FY2025 annual report); 2025 Annual Report (Company leadership biographies; current role cross-checked in FY2025 annual report)

  • About 20 years before joining Syrah; exact dates/roles not itemized: BHP — Various executive roles across commodities and international commercial/operations. Syrah Resources investor presentation / management biographies (Company biography, career section.)

Business failures and setbacks

Tesla alleged sample default cured; final qualification remained outstanding

2025–1 June 2026 · documented · medium materiality

Syrah disclosed in September 2025 that Tesla alleged a default over conforming Vidalia active anode material samples; Syrah said it did not accept that it was in default, and the cure date was extended. On 1 June 2026 Syrah said Tesla accepted it had demonstrated conforming samples and enough progress to cure the alleged default, and withdrew its intent to terminate. The same release said Tesla retained an existing termination right because final qualification had not yet been achieved. The reviewed evidence therefore resolves the alleged sample default but not final qualification risk.

Attribution: Role overlaps event; causation unproven. Shaun Verner was Managing Director, and the 2025/2026 announcements were authorized on behalf of the board by him. This documents his role in communicating the issue and resolution, not personal fault for the alleged default.

Relevance: Material commercial execution and customer-qualification issue for the Managing Director; cure mitigated the immediate termination threat while final qualification remained pending.

Tesla offtake alleged default cure date extended (announcement text, p.1); Tesla offtake alleged default resolved (announcement text, p.1)

Suitability for the current role

Public evidence of fit for Managing Director / Chief Executive Officer

Current role and prior career as stated by issuer · analyst inference · low materiality

The issuer biography reports: Issuer identifies him as Managing Director and CEO; the reviewed current team page contains no career or qualification chronology. Role-fit inference: this experience is relevant to the current Managing Director / Chief Executive Officer responsibilities, but issuer biographies are self-reported and do not independently establish personal delivery outcomes.

Attribution: Responsibility not applicable. This is an analyst role-fit judgment based on the cited role and issuer-reported experience; it does not assign personal responsibility for company outcomes.

Relevance: Relevant to the current Managing Director / Chief Executive Officer role, with evidence quality constrained by the source scope.

Our Team (Syrah Our Team, Board of Directors, lines 57–59)

Evidence gaps

  • The June 2026 cure notice left final qualification outstanding and a customer termination right in place; no later qualification outcome was established from reviewed evidence through cutoff.

  • The June 2026 cure notice left final qualification outstanding and a customer termination right in place; no later qualification outcome was established from reviewed evidence through cutoff.

  • The June 2026 cure notice left final qualification outstanding and a customer termination right in place; no later qualification outcome was established from reviewed evidence through cutoff.

  • The June 2026 cure notice left final qualification outstanding and a customer termination right in place; no later qualification outcome was established from reviewed evidence through cutoff.

  • The June 2026 cure notice left final qualification outstanding and a customer termination right in place; no later qualification outcome was established from reviewed evidence through cutoff.

  • The reviewed issuer material confirms the current title but does not provide a dated full career history or independently verifiable qualifications; prior roles and credentials therefore remain unverified.

  • Open-web searches do not constitute an exhaustive criminal, sanctions, litigation, regulator, safety or credential check; sources outside the documented search scope may exist.